| Literature DB >> 9204908 |
G J Brunn1, C C Hudson, A Sekulić, J M Williams, H Hosoi, P J Houghton, J C Lawrence, R T Abraham.
Abstract
The immunosuppressant rapamycin interferes with G1-phase progression in lymphoid and other cell types by inhibiting the function of the mammalian target of rapamycin (mTOR). mTOR was determined to be a terminal kinase in a signaling pathway that couples mitogenic stimulation to the phosphorylation of the eukaryotic initiation factor (eIF)-4E-binding protein, PHAS-I. The rapamycin-sensitive protein kinase activity of mTOR was required for phosphorylation of PHAS-I in insulin-stimulated human embryonic kidney cells. mTOR phosphorylated PHAS-I on serine and threonine residues in vitro, and these modifications inhibited the binding of PHAS-I to eIF-4E. These studies define a role for mTOR in translational control and offer further insights into the mechanism whereby rapamycin inhibits G1-phase progression in mammalian cells.Entities:
Mesh:
Substances:
Year: 1997 PMID: 9204908 DOI: 10.1126/science.277.5322.99
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728